Qian et al. evaluated 13 studies involving 2841 patients to assess the impact of PD-1/PD-L1 inhibitors combined with neoadjuvant chemotherapy (NCT) in resectable, locally advanced gastric cancer, AEG, and esophageal cancer [19]. This evidence concerns the gene CD274 and gastric cancer.